0
0
KINSHASA, DEMOCRATIC REPUBLIC OF CONGO — A coalition of prominent global health advocacy organizations has formally called on the United States government to immediately share an unapproved, experimental Ebola treatment to help combat an unprecedented and rapidly expanding outbreak in Central Africa. In a joint letter submitted on June 16, 2026, the alliance urged Washington to release its stockpiles of MBP134—a promising pan-ebolavirus monoclonal antibody therapy—for emergency deployment and clinical trials in the Democratic Republic of Congo (DRC) and Uganda, where the deadly and rare Bundibugyo strain of the virus is currently spreading unchecked.
A Direct Appeal for Health Equity
The urgent petition was endorsed by a broad network of international public interest and religious groups, including Public Citizen, the Health Global Access Project (Health GAP), AVAC, and Doctors for the Congregation of Our Lady of Charity of Good Shepherd. The coalition pointed to a stark disparity in global health equity: while U.S. health officials have secured doses of the experimental drug to protect high-risk Americans domestically, the Biden administration has yet to clarify whether it will supply the therapeutic to the African nations currently bearing the brunt of the crisis.
The advocacy groups requested that the U.S. facilitate the immediate distribution of MBP134 “along with any other experimental therapies currently held by the U.S. government.” The current global supply of the drug is managed by the U.S. Biomedical Advanced Research and Development Authority (BARDA), which funded its development by San Diego-based Mapp Biopharmaceutical.
Scale of the Crisis Called ‘Worst Ever’
The demand for international intervention comes as the outbreak climbs to historic proportions. Jean Kaseya, MPH, the head of the Africa Centres for Disease Control and Prevention (Africa CDC), issued a stark warning that the current crisis in the DRC “could be the worst ever” Ebola outbreak, threatening to inflict billions of dollars in regional economic damage.
According to situational reports compiled on June 14, 2026, the DRC alone has recorded 808 confirmed cases and 192 confirmed fatalities. This represents a staggering 24% case fatality rate, a number that epidemiologists fear will rise as contact tracing efforts falter due to regional insecurity and deep funding gaps. The crisis has already expanded across international borders, with Uganda confirming 19 cases, primarily driven by cross-border travel from the DRC’s hard-hit Ituri Province.
In response, the Congolese government has issued an official emergency request for 500 doses of MBP134. Dr. Roger Kamba, the DRC’s Minister of Public Health, stated that the drug is “believed to be effective against the three major strains” of the virus: Zaire, Sudan, and Bundibugyo. Dr. Kamba noted that a preliminary iteration of these monoclonal antibodies successfully helped health workers defeat a challenging Sudan strain outbreak in Uganda in 2025.
What is MBP134?
MBP134 is an investigational bioengineered therapy combining two human monoclonal antibodies—proteins designed to mimic the immune system’s ability to fight off harmful pathogens. Developed by Mapp Biopharmaceutical, the cocktail works by binding to the surface glycoproteins of the virus, effectively blocking it from invading human cells.
[Monoclonal Antibody Cocktail (MBP134)] ──> Binds to Viral Glycoproteins ──> Blocks Cellular Entry
While initially developed to target the Sudan ebolavirus, preclinical animal studies funded by BARDA demonstrated that MBP134 successfully protected ferrets and rhesus macaques from lethal doses of three distinct ebolaviruses, including the Bundibugyo strain. Early Phase 1 human safety trials also indicated the drug was well-tolerated with no severe adverse side effects.
However, regulatory hurdles remain substantial. Mapp Biopharmaceutical notes on its official portal that while preclinical data suggest potential clinical benefits, MBP134 “has not been tested in an appropriately designed and powered clinical efficacy study” in humans. The company maintains that the therapeutic remains strictly an investigational product that is not commercially available.
The Clinical Trial Dilemma
The push by advocacy groups for immediate humanitarian deployment sits in tension with global regulatory frameworks. On May 28, 2026, an independent advisory panel convened by the World Health Organization (WHO) recommended that candidate therapeutics like MBP134, Regeneron’s maftivimab, and Gilead Sciences’ antiviral remdesivir be utilized “exclusively within clinical trials.”
The WHO’s approach prioritizes data generation and ethical research standards over immediate, unmonitored emergency distribution. Public health officials worry that distributing unproven drugs haphazardly outside of a randomized controlled trial framework could lead to inconclusive data, potentially harming future populations by delaying the definitive approval of a truly effective cure.
“Deploying untested treatments outside trials means people who are sick now, or are at risk of becoming sick after being exposed, may not get access to properly evaluated therapies.”
— Extract from WHO Advisory Panel Guidance
Expert Commentary and Counterarguments
Independent medical experts acknowledge the complex ethical tightrope that health authorities must walk during active epidemics.
“The desire to deploy every tool we have during an emergency is completely understandable,” said Dr. Thomas Geisbert, a professor of microbiology and immunology at the University of Texas Medical Branch, who was not involved in the Mapp Biopharmaceutical research. Dr. Geisbert, a leading virologist who helped pioneer the approved Ervebo vaccine for the Zaire strain, noted that while animal data for single-dose treatments against Bundibugyo are highly encouraging, animal success does not always translate perfectly to human biology. “Most candidate treatments for this specific strain are still stuck at the preclinical stage. Controlled evaluation is critical.”
Dr. Kamba of the DRC Health Ministry echoed this pragmatic reality, confirming that because human data are highly limited, the DRC expects to administer any received doses strictly within a structured trial protocol. “As it has mainly been tested in monkeys… we will receive it within the framework of a clinical trial,” Dr. Kamba clarified.
The Bundibugyo Treatment Gap
The ongoing debate underscores a critical gap in global health preparedness: there are currently zero FDA-approved antiviral treatments or vaccines specifically indicated for the Bundibugyo strain.
Licensed therapies like Inmazeb and Ebanga are highly effective but are strictly formulated for the Zaire ebolavirus. Because of this, current medical care for Bundibugyo patients is restricted entirely to optimized supportive care.
[Current Deployed Interventions for Bundibugyo Disease]
│
┌───────────────────────┴───────────────────────┐
▼ ▼
[Supportive Care Only] [Investigational Path]
• Aggressive intravenous rehydration • Adaptive clinical trials
• Electrolyte correction • Monoclonal antibody testing
• Symptom management (fever/pain) • Post-exposure prophylaxis
Several vaccine candidates are currently being fast-tracked, including a viral vector candidate from IAVI, but experts estimate it will not be ready for field trials for seven to nine months. Another candidate developed by Oxford University and the Serum Institute of India could be ready within two to three months, pending additional animal safety data.
Public Health and Logistical Uncertainties
Considerable operational challenges shroud the deployment of MBP134. BARDA has not publicly disclosed the exact number of doses currently sitting in the U.S. strategic national stockpile, leaving it unclear if there is sufficient supply to meet the DRC’s request for 500 doses while preserving domestic bio-defense reserves. Furthermore, the U.S. Department of Health and Human Services has not issued an official response to the coalition’s June 16 letter.
Anecdotal medical data have surfaced; an American citizen who recently contracted Ebola while working in the DRC was reportedly treated with MBP134 under a compassionate use exemption and is reportedly recovering well. However, epidemiologists stress that a single recovery constitutes an anecdote, not scientific proof of efficacy.
Ultimately, the resolution of this standoff will carry deep implications for global health equity, defining how the international community balances the rigid demands of scientific validation with the moral imperative to save human lives during an active health emergency.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
- https://www.reuters.com/business/healthcare-pharmaceuticals/advocacy-groups-urge-us-share-experimental-ebola-drug-outbreak-trials-2026-06-16/
